mRNA-based Universal Flu Vaccine Enters Human Trial
TL;DR Summary
A Phase 1 clinical trial of a universal mRNA-based influenza vaccine is underway at Duke University, developed by the National Institute of Allergy and Infectious Diseases' Vaccine Research Center. The trial will evaluate the immune response and safety of the vaccine in 50 participants aged 18-49 over 12 months. The vaccine combines the H1ssF nanoparticle vaccine with messenger RNA to deliver a more efficient, targeted immune response.
Topics:health#clinical-trial#duke-university#flu-vaccine#health#mrna#national-institute-of-allergy-and-infectious-diseases
- Human Trial of mRNA Universal Flu Vaccine Begins - Slashdot Slashdot
- Long-sought universal flu vaccine: mRNA-based candidate enters clinical trial Ars Technica
- WATCH: Early stage trial for universal flu vaccine Channel 3000 / News 3 Now
- Vaccine trial | Duke Health's new universal flu vaccine trial uses mRNA technology, aims to enhance protection WTVD-TV
- Scientists working on 'universal' flu vaccine that could last years CBS Boston
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
77%
290 → 67 words
Want the full story? Read the original article
Read on Slashdot